4OTG
| Crystal Structure of PRK1 Catalytic Domain in Complex with Lestaurtinib | 分子名称: | Lestaurtinib, Serine/threonine-protein kinase N1 | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | 登録日 | 2014-02-13 | 公開日 | 2014-08-27 | 最終更新日 | 2022-12-07 | 実験手法 | X-RAY DIFFRACTION (2.6 Å) | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes. Plos One, 9, 2014
|
|
4OTH
| Crystal Structure of PRK1 Catalytic Domain in Complex with Ro-31-8220 | 分子名称: | BISINDOLYLMALEIMIDE IX, Serine/threonine-protein kinase N1 | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | 登録日 | 2014-02-13 | 公開日 | 2014-08-27 | 最終更新日 | 2018-01-24 | 実験手法 | X-RAY DIFFRACTION (1.8 Å) | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes. Plos One, 9, 2014
|
|
4OTI
| Crystal Structure of PRK1 Catalytic Domain in Complex with Tofacitinib | 分子名称: | 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile, Serine/threonine-protein kinase N1 | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | 登録日 | 2014-02-13 | 公開日 | 2014-08-27 | 最終更新日 | 2018-01-24 | 実験手法 | X-RAY DIFFRACTION (1.93 Å) | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes. Plos One, 9, 2014
|
|
4OTD
| Crystal Structure of PRK1 Catalytic Domain | 分子名称: | Serine/threonine-protein kinase N1 | 著者 | Chamberlain, P.P, Delker, S, Pagarigan, B, Mahmoudi, A, Jackson, P, Abbassian, M, Muir, J, Raheja, N, Cathers, B. | 登録日 | 2014-02-13 | 公開日 | 2014-08-27 | 最終更新日 | 2018-01-24 | 実験手法 | X-RAY DIFFRACTION (2 Å) | 主引用文献 | Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes. Plos One, 9, 2014
|
|